New-onset Adult-onset Still's Disease Following COVID-19 Vaccination: Three Case Reports and a Literature Review

Mayumi Matsuda; Yu Funakubo Asanuma; Kazuhiro Yokota; Sakon Sakai; Hiroaki Yazawa; Takashi Maruyama; Takuma Tsuzuki Wada; Yasuto Araki; Toshihide Mimura

doi:10.2169/internalmedicine.0590-22

CASE REPORTS

New-onset Adult-onset Still's Disease Following COVID-19 Vaccination: Three Case Reports and a Literature Review

Mayumi Matsuda, Yu Funakubo Asanuma, Kazuhiro Yokota, Sakon Sakai, Hiroaki Yazawa, Takashi Maruyama, Takuma Tsuzuki Wada, Yasuto Araki, Toshihide Mimura

Author information

Mayumi Matsuda
Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan
Yu Funakubo Asanuma
Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan
Kazuhiro Yokota
Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan
Sakon Sakai
Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan
Hiroaki Yazawa
Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan
Takashi Maruyama
Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan
Takuma Tsuzuki Wada
Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan
Yasuto Araki
Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan
Toshihide Mimura
Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Japan

Keywords: adult-onset Still's disease, COVID-19 vaccine, innate immune response

JOURNAL OPEN ACCESS

2023 Volume 62 Issue 2 Pages 299-305

DOI https://doi.org/10.2169/internalmedicine.0590-22

Browse “Advance online publication” version

Details

Abstract

Since December 2020, coronavirus disease 2019 (COVID-19) vaccines have been distributed in most countries to prevent the onset and aggravation of COVID-19. There is little information regarding the long-term safety of the vaccines. We report three cases and a literature review of new-onset adult-onset Still's disease (AOSD) that occurred following COVID-19 vaccination. Our cases include moderate to severe AOSD, and two were complicated with macrophage activation syndrome. Seventeen cases of new-onset or relapse of AOSD following COVID-19 vaccination, including 14 identified in the literature review and our 3 patients, were all treated successfully with glucocorticoid therapy, immunosuppressive drugs, or biologic agents.

Corresponding author

Register with J-STAGE for free!